Risk Disclosure In Drug Ads Will Be FDA’s Focus After House Defeats DTC Ban

The revised language on direct-to-consumer advertising in the FDA safety bills pending in Congress no longer allows the agency to ban ads, but creates a number of new disclosure requirements for the spots